<DOC>
	<DOCNO>NCT00006343</DOCNO>
	<brief_summary>RATIONALE : Biological therapy interferon-alfa STI571 may interfere growth cancer cell . It yet know STI571 effective interferon alfa plus cytarabine chronic myelogenous leukemia . PURPOSE : Randomized phase III trial compare effectiveness STI571 interferon alfa plus cytarabine treating patient newly diagnose chronic myelogenous leukemia .</brief_summary>
	<brief_title>STI571 Compared With Interferon Alfa Plus Cytarabine Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Compare time treatment failure overall survival patient newly diagnose , previously untreated , Philadelphia chromosome positive , chronic phase chronic myelogenous leukemia treat STI571 v interferon alfa combine cytarabine . II . Compare quality life disease treatment related toxicity patient treat 2 regimen . III . Compare rate duration complete hematologic response ( CHR ) major cytogenetic response ( MCR ) patient treat 2 regimen . IV . Compare rate duration MCR CHR attributable crossover therapy patient crossover receive STI571 OR interferon alfa combine cytarabine . V. Compare tolerability safety regimens patient . VI . Determine population pharmacokinetics STI571 patient . OUTLINE : This randomize , open label , crossover , multicenter study . Patients randomize one two treatment arm : Arm I : Patients receive oral STI571 daily . Arm II : Patients receive interferon alfa ( IFN-A ) subcutaneously ( SQ ) daily . Gradual intrapatient dose escalation perform target dose IFN-A achieve . Patients also receive cytarabine SQ daily 10 day every month . Cytarabine discontinue complete cytogenetic response achieve confirm two consecutive occasion 3 month apart . Both arm : Courses repeat monthly absence progression accelerate phase blast crisis , unacceptable toxicity . Patients complete hematologic response 6 month , major cytogenetic response year 2 , loss complete hematologic response ( without progression accelerate blastic phase ) discontinue treatment arm originally randomize begin treatment arm . Crossover course repeat monthly absence progression accelerate phase blast crisis , unacceptable toxicity . Quality life assess prior study ; monthly first 6 month study ; 9 , 12 , 18 , 24 month ; time crossover ( applicable ) ; treatment discontinuation year 2 ( applicable ) . All patient follow every 3 month 8 year . PROJECTED ACCRUAL : A total 850 patient ( 425 per arm ) accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Cytogenetically proven Philadelphia chromosome positive chronic phase chronic myelogenous leukemia ( CML ) Initial diagnosis within past 6 month No prior chemotherapy , include regimen use peripheral blood progenitor cell ( PBPC ) mobilization PBPC transplantation , CML except hydroxyurea Must meet follow criterion : Blasts peripheral blood bone marrow le 15 % Blasts plus promyelocytes peripheral blood bone marrow le 30 % Basophils peripheral blood le 20 % Platelet count least 100,000/mm3 No extramedullary leukemic involvement except spleen liver No patient sibling bone marrow donor available allogeneic bone marrow transplantation elect first line therapy PATIENT CHARACTERISTICS : Age : 18 70 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : See Disease Characteristics Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) SGOT SGPT great 1.5 time ( ULN ) INR PTT great 1.5 time ULN Renal : Creatinine great 1.5 time ULN Cardiovascular : No angina No New York Heart Association class III IV heart disease Other : No uncontrolled medical disease , diabetes mellitus , thyroid dysfunction , neuropsychiatric disorder , infection HIV negative Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception No malignancy within past 5 year except basal cell skin cancer carcinoma situ cervix No history noncompliance medical regimen potential noncompliance PRIOR CONCURRENT THERAPY : Biologic therapy : Concurrent leukapheresis allow first month study No concurrent allogeneic bone marrow transplantation Concurrent anagrelide allow first 3 month study Chemotherapy : See Disease Characteristics Concurrent hydroxyurea allow first 3 month study Endocrine therapy : No concurrent systemic steroid 2 week Radiotherapy : Not specify Surgery : Greater 4 week since prior major surgery recover Other : No prior investigational agent No concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>chronic myelogenous leukemia , BCR-ABL1 positive</keyword>
</DOC>